1 Daughaday WH. Pituitary Gigantism. Endocrinol Metab Clin Nor Am 1992;21(3):633-46.

2 Alexander L, Appelton D, Hall R, et al: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxford) 1980;12:71-79.

3 Extabe J, Gaztambide S, Latorre P, Vasquez J. Acromegaly: an epidemiological study. J Endocrinol Invest 1993;16: 181-187.

4 Sotos JF. Overgrowth, section II. Clin Pediatr 1996;35(11):579-590.

5 Melmed S. Acromegaly. N Eng J Med 1990;322:966-977.

6 Zimmerman D, Young WF, Ebersold MJ, Scheithauer BW, Kovacs K, Horvath E, Whitaker MD, Eberhardt NL, Downs TR, Frohman LA. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab 1993; 76(1): 216-222.

7 Moran A, Asa SL, Kovacs K, Horvath E, Singer W, Sagman U, Reubi J-C, Wilson CB, Larson R, Pescovitz OH. Gigantism due to pituitary mammosomatotroph hyperplasia. N Eng J Med 1990; 323(5):322-326.

8 Felix IA, Horvath E, Kovacs K, Smyth HS, Killinger DW, Vale J. Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol 1986;71:76-82.

9 Dubuis JM, Deal CL, Drews RT, Goodyer CG, Lagace G, Asa SL, Van Vliet G, Collu R. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: a possible pathogenetic mechanism. Clin Endocrinol 1995;42(5):539-49.

10 Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr 1992; 120: 931-934.

11 Blumberg DL, Sklar CA, David R, Rothenberg S, Bell J. Acromegaly in an infant. PEDIATRICS 1989;83(6):998-1002.

12 Vidal S, Horvath E, Kovacs K, Lloyd RV, Smyth HS. Reversible transdifferentiation: interconversion of somatotrophs and lactotrophs in pituitary hyperplasia. Mod Path 2001;14(1):20-8.

13 Araki Y, Sakai N, Andoh T, Yoshimura S, Yamada H. Central neurocytoma presenting with gigantism: case report. Surg Neurol 1992;38(2):141-5.

14 Asada H, Otani M, Furuhata S, Inoue H, Toya S, Ogawa Y. Mixed pituitary adenoma and gangliocytoma associated with acromegaly—case report. Neurologia Medico-Chirurgica 1990;30(8):628-32.

15 Asa SL, Scheithauer BW, Bilbao JM, Horvath E, Ryan N, Kovacs K, Randall RV, Laws ER, Singer W, Linfoot JA, Thorner MO, Vale W. A case for hypothalamic acromegaly: A clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 1984;58(5): 796-803.

16 Faglia G, Arosio M, Bazzoni N. Ectopic Acromegaly. Endocrinol Metab Clin N Am 1992;21(3): 575-595.

17 Beuschlein F, Strasburger CJ, Siegerstetter V, Moradpour D, Lichter P, Bidlingmaier M, Blum HE, Reincke M. Acromegaly cuased by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000;342(25):1871-1876.

18 Doga M, Bonadonna S, Burattin A, Guistina A. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol 2001;12 Suppl 2: S89-94.

19 Madonna D, Kendler A, Soliman AM. Ectopic growth hormone-secreting pituitary adenoma in the sphenoid sinus. Ann Otol Rhinol Laryngol 2001;110(1): 99-101.

20 Osella G, Orlandi F, Carace P, Ventura M, Deansreis D, Papotti M, Bongiovanni M, Angeli A, Terzolo M. Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest 2003;26(2):163-9.

21 Costin G, Fetterman RA, Kogut MD. Hypothalamic gigantism. J Pediatr 1973;83:419-425.

22 Drimmie FM, Maclennan AC, Nicolls JAR, Simpson E, McNeill E, Donaldson MDC. Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol 2000;53:535-538.

23 Duchowny MS, Katz R, Bejar RL. Hypothalamic mass and gigantism in neurofibromatosis: treatment with bromocriptine. Ann Neurol 1984;15:302-304.

24 Drake AJ, Lowis SP, Boufett E, Crowne EC. Growth hormone hypersecretion in a girl with neurofibromatosis type 1 and an optic glioma: resolution following chemotherapy. Horm Res 2000;53(6):305-8.

25 Fuqua JS, Berkovitz GD. Growth hormone excess in a child with neurofobromatosis type 1 and optic pathway tumor: A patient report. Clin Pediatr 1998; 37:749-752.

26 Manski TJ, Haworth CS, Duval-Arnould J, Rushing EJ. Optic pathway glioma infiltrating into somatostatinergic pathways in a young boy with gigantism. J Neurosurg 1994;81:595-600.

27 Waguespack, SG, Eugster EA, Pescovitz OH. Growth hormone (GH) excess in a child with neurofibromatosis type 1 (Nf1) and optic pathway glioma. Pediatr Res 2001; 49(6 Suppl 2 of 2):82A Abstract

28 Foster CM. Endocrine manifestations of McCune-Albright syndrome. The Endocrinologist 1993;3(5):359-364.

29 Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.

30 Collins MT, Shenker A. McCune-Albright syndrome: new insights. Curr Opin Endocrinol Metab 1999;6:119-125.

31 Lumbroso S, Paris F, Sultan C. McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab 2002;15 Suppl 3:875-82.

32 Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine 1996;75: 171-184.

33 Tinschert S, Gerl H, Gewies A, Jung, H-P, Nürnberg P. McCune-Albright syndrome: Clinical and Molecualr evidence of mosaicism in an unusual giant patient. Am J Med Genet 1999;83:100-108.

34 Vogl TJ, Nerlich A, Dresel SH, Bergman C. CT of the “Tegernsee Giant”: juvenile gigantism and polyostotic fibrous dysplasia. J Comput Ass Tom 1994;18(2): 319-322.

35 Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002;87(11):5104-12.

36 Dötsch J, Kiess W, Hänze J, Repp R, Lüdecke D, Blum WF, Rascher W. Gs? mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996;81(11):3839-3842.

37 Zumkeller W, Jassoy A, Lebek S, Nagel M. J Pediatr Endocrinol 2001; 14(5):553-559.

38 Moran A, Pescovitz OH. Long term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocrinol J 1994;2:111-113.

39 Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989; 68(6): 1148-54.

40 Shimon I, Melmed S. Genetic basis of endocrine disease. J Clin Endocrinol Metab 1997;82(6):1675-1681.

41 Motomura T, Kasayama S, Takagi M, Kurebayashi S, Matsui H, Hirose T, Miyashita Y, Yamauchi-Takihara K, Yamamoto T, Okada S, Kishimoto T. Increased interleukin-6 production in mouse osteoblastic MC3T3-E1 cells expressing activating mutant of the stimulatory G protein. J Bone Miner Res 1998;13:1084-1091.

42 Skogseid B, Rastad J, Öberg K. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin N Am 1994;23(1):1-15.

43 Larsson C, Skogseid B, Öberg K, Nakamura Y, Nordenskjold N. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332:85-87.

44 Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN-1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-1634.

45 Bassett JHD, Forbes SA, Pannett AAJ, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-244.

46 Mutch MG, Dilley WG, Sanjurjo F, et al. Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. Hum Mutat 1999;13:175-185.

47 Boggild MD, Jenkinson S, Pistorello M et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 1994;78:387-392.

48 Carty SE, Helm AK, Amico JA et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surg 1998;124:1106-1114.

49 Stratakis CA, Schusshein DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, Skarulis MC, Weil RJ, Lubensky IA, Zhuang Z, Oldfield EH, Marx SJ. Pituitary macroadenoma in a 5-year-old:An early expression of multiple endocrine neoplasia type !. J Cin endocirnol Metab 2000;85:4776-4780.

50 Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Concensus guidelines for diagnosis and therapy of MEN type 1 and 2. J Clin Endocrinol Metab 2001;86:5658-5671.

51 Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VLW. The complex of myxomas, skin pigmentation and endocrine overactivity. 1985 Medicine (Baltimore); 64:270-283.

52 Stratakis CA. Genetics of Carney complex and related familial lentiginosis and other multiple tumor syndromes. Pediatr Pathol Mol Med. 2000;19:41-68.

53 Stratakis CA, Carney JA, Lin J-P, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. 1995 J Clin Invest; 97:699-705.

54 Kirschner LS, Carney JA, Pack S et al. Mutations of the PRKAR1A gene in patients with Carney complex. 2000 Nat Genet;26:89-92.

55 Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type 1-alpha regulatory subunit in patients with Carney complex. Nat Genet 2000;26(1):89-92.

56 Sandrini F, Stratakis C. Clinical and molecular genetics of Carney complex. Mol Genet Metab 2003;78(2):83-92.

57 Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the carney comples: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041-4046.

58 Pack, SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “Complex of spotty skin pigmentation , myxomas, endocrine overactivity and schwannomas” (Carney Complex). J Clin Endocrinol Metab 2000;85:3860-3865.

59 Raff SB, Carney JA, Krugman D, Doppman JL, Stratakis CA. Prolactin secretion abnormalities in patients with the “syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas”. J Pediatr Endocrinol 2000;13(4):373-9.

60 Gadelha MR, Kineman RD, Frohman LA. Familial somatotropinoma: Clinical and Genetic aspects. Endocrinologist 1999;9:277-285.

61 Matsuno A, Teramoto A, Yamada S, Kitanaka S, Tanaka T, Sanno N, Osamura RY, Kirino T. Gigantism in sibling unrelated to multiple endocrine neoplasia: case report. Neurosurg 1994; 35(5): 952-5.

62 Gadelha MR, Prezant TR, Une KN, Glick RP, Moskal SF, Vaisman M, Melmed S, Kineman RD, Frohman LA. Loss of heterozygosity on chromosme 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type 1 gene. J Clin Endocrinol Metab 1999;84(1):249-256.

63 Frohman LA. Isolated familial somatotropinomas: clinical and genetic considerations. Trans Am Clin Climatol Ass 2003;114:165-77.

64 Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman LD, Frohman LA. Isolated familial somatotropinomas:Establishment of linkage to chromsome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 2000;85(2):707-714.

65 Jorge BH, Agarwal SK, Lando VS, Salvatori R, Barbero RB, Abelin N, Levine MA, Marx SJ, Toledo SPA. Study of the multiple endocrine neoplasia type 1, growth hormone-releaseing hormone receptor, Gs? and Gi2? genes in isolated familia acromegaly. J Clin Endocrinol Metab 2001;86:542-544.

66 Barkan AL, Beitins IZ, Kelch RP. Plasma insulin like growth factor-1/somatomedin C in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67(1):69-73.

67 Kuzuya T, Matsuda A, Sakamoto Y, Yamamoto K, Saito T, Yoshida S. A case of pituitary gigantism who had two episodes of diabetic ketoacidosis followed by complete recovery of diabetes. Endocrinol Japon 1983;30(3):329-34.

68 Alvi NS, Kirk JM. Pituitary gigantism causing diabetic ketoacidosis. J Pediatr Endocriol Metab 1999;12(6):907-9.

69 Grellier P, Chanson P, Casadevall N, Abboud S, Schaison G. Remission of polycythemia vera after surgical cure of acromegaly. Ann Intern Med 1996;124:495-49.

70 Eugster EAE, Fisch M, Walvoord EC, DiMeglio LA, Pescovitz OH. Low hemoglobin levels in children with idiopathic growth hormone deficiency. Endocrine 2002;18(2):135-6.

71 Chapman IM, Hartman ML, Strane M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower post-glucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994;78:1312-1317.

72 Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646-2652.

73 Freda PU, Nuruszzaman AT, Reyes CM, Sundde RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-1 levels. J Clin Endocrinol Metab 2004;89(2):495-500.

74 Patel YC, Ezzat S, Chik CL, Rorstad OP, Serri O, Ur E, Wilkins GE. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clin Invest Med 2000;23(3):172-187.

75 Le Roith D. Seminars in medicine of the Beth Israel Center. Insulin-like growth factors. N Engl J Med 1997;336(9):633-640.

76 Holl RW, Bucher P, Sorgo W, Heinze E, Homoki J, Debatin K-M. Horm Res 1999;51:20-24.

77 Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Werder KV, Melmed S. Concensus. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85(2):526-529.

78 Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.

79 Gittoes NJL et al. Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. Q J Med 1999;92:741-745.

80 Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.

81 Laws Jr ER, Thapar K. Pituitary surgery in advances in pituitary tumor therapy. 1999;28:119-131.

82 Abe T, Tara LA, Lüdecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence:Features and results of transnasal surgery. Neurosurg 1999;45(1):1-10

83 Sklar C. Endocrine complications of the successful treatment of neoplastic diseases in childhood. Grow Genet Horm 2001;17(3):37-42.

84 Swords FM, Allan CA, Plowman PN, Sibtain A, Evanson J, Chew SL, Grossman AB, Besser GM, Monson JP. Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab 2003;88(11):5334-40.

85 Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio. Gamma-knife radiosurgery in acromegaly: a 4 year follow-up study. J Clin Endocrinol Metab 2003;88(7):3105-12.

86 Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, et al. Molecular biology of somatostatin receptor subtypes. Metab 1996;45(8 suppl 1):31-38.

87 Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly: A randomized, multicenter study. Ann Intern Med 1992;117(9):711-8.

88 Newman C, Melmed S, George A et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3104-3109.

89 Feuillan PH, Jones J, Ross JL. Growth hormone hypersecretion in a gilr with McCune Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab 1995;80:1357-1360.

90 Näntö-Salonen K, Koskinen P, Sonninen P, Toppari J. Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy. Acta Paediatr 1999;88:29-33.

91 Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013-3018.

92 Flogstad AK, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997; :23-28.

93 Drange MR, Melmed S. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab 1998;83(9):3104-3109.

94 Maheshwari HG, Prezant TR, Herman-Bonert V, Shahinian H, Kovacs K, Melmed S. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 2000;85(9):3409-3416.

95 Hofland LJ, Hoek JVD, Koetsveld PMV, Herder WWD, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, Lely AJVD, Beckers A, Lamberts SWJ. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone-and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89(4):1577-1585.

96 Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA. Treatment of acromegaly with the growth hormone-receptor antagonaist pegvisomant. N Engl J Med 2000;342:1171-7.

97 Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational desing of potent antagonists to the human growth hormone receptor. Science 1992;256:1677-1680.

98 Van der Lely A, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1744.

99 Muller AF, Kopchick JJ, Flyvbjerg A, Jan van der Lely A. Growth hormone receptor antagonists. 2004;89(4):1503-1511.

100 Drop SLS, De Waal WJ, Keizer-Schrama SMPFD. Sex steroid treatment of constitutionally tall stature. Endocrin Rev 1998;19(5):540-558.

101 Minegawa M, Yasuda T, Someya T, Kohno Y, Saeki N, Hashimot Y. Effects of octreotide infusion, surgery and estrogen on suppression of height increase and 20K growth hormone ratio in a girl with gigantism due to a growth hormone-secreting macroadenoma. Horm Res 2000;53(3):157-60.

102 Lu PW, Silink M, Johnston I, Cowell CT, Jimenez M. Pituitary gigantism. Arch Dis Child 1992;67(8):1039-41.

103 Sotos JF, Dodge PR, Muirhead D, Crawford JD, Talbot NB. Cerebral gigantism in childhood. N Eng J Med 1964;271:109-116.

104 Cole TRP, Hughes HE. Sotos syndrome: a study of the diagnostic criteria and natural history. J Med Genet 1994;31:20-32.

105 Agwu JC, Shaw NJ, Kirk J, Chapman S, Ravine D, Cole TR. Growth in Sotos syndrome. Arch Dis Child 1999;80(4):339-342.

106 Sotos JF. Overgrowth, section V, Syndromes and other disorders associated with overgrowth. Clin Ped 1997;91-103.

107 Mauceri L, Sorge G, Baieli S, Rizzo R, Pavone L, Coleman M. Aggressive behavior in patients with Sotos syndrome. Ped Neurol 2000;22(1):64-67.

108 Brown WT, Wisnieski KE, Sudhalter V, Keogh M, Tsiouris J, Miezejeski C, Schaefer GB. Identical twins discordant for Sotos syndrome. Am J Med Genet 1998;79(4):329-33.

109 Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T, Ohashi H, Naritomi K et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002;30(4):365-6.

110 Visser R, Matsumoto N. Genetics of Sotos syndrome. Curr Opin Pediatr 2003;15(6):598-606.

111 Beckwith JB. Macroglossia, omphalocele, adrenal cytomegaly;gigantism and hyperplastic visceromegaly. Birth Defects: Original Article Series 1969;5:188-196.

112 Wiedemann HR. Complexe malformatif familial avec hernie ombilicale et macroglossie-un “syndrome nouveau”? J Genet Hum 1964;13:223

113 Sotos JF. Overgrowth, section 1V, Genetic syndromes and other disorders associated with overgrowth. Clin Ped 1997;157-170.

114 Pettenati MJ, Haines JL, Higgins RR, Wappner RS, Palmer CG, Weaver DD. Weidemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 1986;74:143-154.

115 Wiedemann HR. Tumors and hemihypertrophy associated with Wiedemann-Beckwith syndrome. Eur J Pediatr 1983;141:129.

116 Borer JG, Kaefer M, Barnewolt CE, Elias ER, Hobbs N, Retik AB, Peters CA. Renal findings on radioloical followup of patients with Beckwith-Wiedemann syndrome. J Urol 1999;161(1):235-9.

117 DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome registry. J Pediatr 1998;132(3 pt 1):398-400.

118 Slavotinek A, Gaunt L, Donnai D. Patenrlly inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome. J Med Genet 1997;34(10):819-826.

119 Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79(4):279-283.

120 Lin AE, Neri G, Hughes-Benzie R, Weksberg R. Cardiac anomalies in the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1999;83(5):378-381.

121 Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutations in GPC3, a glypican gene, cuase the Simpson-Golabi-Behmal overgrowth syndrome. Nat Genet 1996;12(3):241-247.

122 DeBaun MR, Ess J, Saunders S. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation and cancer predispostion. Mol Genet Metab 2001;72(4):279-286.

123 Mariani S, Iughetti L, Bertorelli R, Coviello D, Pellegrini M, Forabosco A, Bernasconi S. Genotype/phenotype correlations of males affected by Simpson-Golabi-Behmel syndrome with GPC3 gene mutations: patient report and review of the literature. J Pediatr Endocrinol Metab 2003;16(2):225-32.

124 Toretsky JA, Zitomersky NL, Eskenazi AE, Voigt RW, Strauch ED, Sun CC, Huber R, Meltzer SJ, Schlessinger D. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hem Onc 2001;23(8):496-499.

125 Filmus J. Glypicans in growth control and cancer. Glycobiology 2001;11(3):19R-23R

126 Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, Stevens C, Wilkins-Haug L, Day-Salvatore D, Yong SL, Geraghty MT, Squire J, Weksberg R. GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet 2001;102(2):161-168.

127 Weaver DD, Graham CB, Thomas IT, Smith DW. A new overgrowth syndrome with accelerated skeletal maturation, unusual facies and camptodactyly. J Pediatr 1974;84:547-552.

128 Kelly TE, Alford BA, Abel M. Cervical spine anomalies and tumors in Weaver syndrome. Am J Med Genet 2000;95(5):492-495.

129 Proud VK, Braddock SR, Cook L, Weaver DD. Weaver syndrome: autosomal dominant inheritance of the disorder. Am J Med Genet 1998;79(4):305-310.

130 Rio M, Clech L, Amiel J, Faivre L, Lyonnet S, Le Merrer M, Odent S, Lacomb D, Edery P, Brauner R, Raoul O, Gosset P, Prieur M, Vekemans M, Munnich A, Colleaux L, Cormier-Daire V. Specturm of NSD1 mutations in Sotos and Weaver syndromes. J Med Genet 2003;40(6):436-40.